Abstract
Aims
In Soli‐CGM, treatment with iGlarLixi (insulin glargine 100 U/mL and lixisenatide 33 μg/mL) in insulin‐naive adults with suboptimally controlled type 2 diabetes (T2D; haemoglobin A1c 9%–13% on ≥2 oral antihyperglycaemic agents (OADs) ± glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) therapy) increased time in range (TIR; primary endpoint) from 26.4% at baseline to 52.7% at Week 16. This exploratory analysis examined the impact of treatment with iGlarLixi on patient‐reported treatment satisfaction.
Materials and Methods
Soli‐CGM was a single‐arm, 16‐week, multicentre, interventional, open‐label, phase 4 study using blinded continuous glucose monitoring (CGM; FreeStyle Libre Pro) to assess glycaemic metrics (N = 124). CGM data were collected for a 2‐week period before initiation of iGlarLixi, and after treatment with iGlarLixi (Weeks 14–16). Treatment satisfaction was assessed using the Diabetes Medication Treatment Satisfaction Tool (DM‐SAT, which comprises four domains: well‐being, medical control, lifestyle and convenience), at baseline and end‐of‐treatment. Association of TIR and overall satisfaction (sum of all items) was also assessed.
Results
Overall, 118 (95.9%) and 107 (87.0%) participants completed the DM‐SAT at baseline and Week 16, respectively. Mean overall score increased by 0.18, from 0.59 (baseline) to 0.78 (Week 16). A trend in improvement in score was observed in all domains. Improvement in TIR had a positive, but weak, trend of association with improvement in overall treatment satisfaction (mean r = 0.14).
Conclusions
In people with T2D suboptimally controlled on ≥2 OADs ± GLP‐1 RA, 16 weeks' treatment with iGlarLixi resulted in a trend of improvement in treatment satisfaction.